Immunotherapy Extends Survival for 60% of Stage 4 Melanoma Patients Beyond 10 Years
Updated
Updated · WPLG Local 10 · May 28
Immunotherapy Extends Survival for 60% of Stage 4 Melanoma Patients Beyond 10 Years
7 articles · Updated · WPLG Local 10 · May 28
Stage 4 melanoma patients now live 10 years or longer in about 60% of cases with immunotherapy, a sharp shift for a cancer that once carried a far bleaker outlook.
The drugs work by activating the patient’s immune system to recognize and attack melanoma after the disease has spread to organs such as the lungs and liver.
Jeff Hill, 77, has received regular infusions for 10 years after metastatic melanoma was found in his lungs and liver; his cancer has since disappeared.
Immunotherapy still carries risks: the immune response can also attack healthy joint tissue, causing inflammation and arthritis, though doctors said those symptoms fade after treatment ends in about half of patients.
Beyond today's treatments, are 'triple-kill' nanobombs the future of fighting cancer?
As miracle cancer drugs become reality, are they creating a new class of inequality?
10-Year Survival in Advanced Melanoma: How Immunotherapy is Transforming Outcomes, Access, and Quality of Life (2024 Update)
Overview
A new era of hope is emerging for patients with advanced melanoma, as groundbreaking long-term data from clinical trials reveal a significant shift in prognosis. The latest updates from the CheckMate 067 trial show that the sustained efficacy of combination immunotherapy regimens, especially the use of nivolumab and ipilimumab, is making extended survival—including the possibility of 10-year survival—a reality for many. This progress is driven by the remarkable long-term safety and effectiveness of these treatments, offering patients and clinicians renewed optimism and clearer expectations for the future of advanced melanoma care.